Back to Search
NANCY SHULMAN, PHARM.D.
PHARM.D.
Pharmacotherapy Pharmacist
NPI: 1538259460Individual
Specialties, Licenses & Credentials
Pharmacotherapy PharmacistPrimary
Pharmacist — Pharmacotherapy
Code: 1835P1200X
RPH 53289(CA)
Clinical Trials (1)
1
Linked Trials
0
Recruiting
1
With Results
Research & Publications (20)
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.
PMID 23589670·Blood·2013
2-rct
Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials.
PMID 18615598·Cytometry A·2008
8-other
Interactions between non-nucleoside reverse transcriptase inhibitor and nucleoside reverse transcriptase inhibitor mutations: phenotypes and mechanisms.
PMID 19372872·Curr Opin HIV AIDS·2007
8-other
Case files from Stanford University Medical Center: ten years of HAART: a long wait for full HIV suppression.
PMID 17435619·MedGenMed·2007
5-case
Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays.
PMID 15851917·J Acquir Immune Defic Syndr·2005
8-other
A review of HIV-1 resistance to the nucleoside and nucleotide inhibitors.
PMID 14754429·Curr Drug Targets Infect Disord·2003
6-review
Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.
PMID 12435695·Antimicrob Agents Chemother·2002
8-other
Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.
PMID 12394789·J Acquir Immune Defic Syndr·2002
3-trial
Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy.
PMID 11468426·J Acquir Immune Defic Syndr·2001
3-trial
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
PMID 11416714·AIDS·2001
8-other
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response.
PMID 10839657·J Acquir Immune Defic Syndr·2000
8-other
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.
PMID 19301976·J Infect Dis·2009
8-other
Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients.
PMID 18221530·Retrovirology·2008
8-other
More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175.
PMID 17570122·J Infect Dis·2007
2-rct
Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.
PMID 16603849·AIDS·2006
8-other
Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.
PMID 15983922·Clin Infect Dis·2005
8-other
Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.
PMID 15608522·J Acquir Immune Defic Syndr·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 20940 BURBANK BLVD, HOME INFUSION PHARMACY
WOODLAND HILLS, CA 91367 - Phone
- (818) 719-4300
Quick Facts
- NPI
- 1538259460
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile